Tactile Medical to Release Second Quarter of Fiscal Year 2025 Financial Results on August 4, 2025

Rhea-AI Summary

Tactile Medical (NASDAQ: TCMD), a medical technology company specializing in at-home therapies for chronic conditions, has scheduled its Q2 2025 earnings release for August 4, 2025 after market close.

The company will host a conference call with Q&A at 5:00 p.m. Eastern Time on the same day. Investors can participate via phone (877-407-3088 for domestic, 201-389-0927 for international) using access code 13754589, or through a live webcast on the company's investor relations website.

Tactile Medical focuses on treating conditions including lymphedema, lipedema, chronic venous insufficiency, and chronic pulmonary disease, helping patients manage their care at home.

MINNEAPOLIS, July 21, 2025 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chronic disorders, today announced that second quarter of fiscal year 2025 financial results will be released after the market closes on Monday, August 4, 2025.

Management will host a conference call with a question and answer session at 5:00 p.m. Eastern Time on August 4, 2025, to discuss the results of the quarter. Those who would like to participate may dial 877-407-3088 (201-389-0927 for international callers) and provide access code 13754589. A live webcast of the call will also be provided on the investor relations section of the Company's website at investors.tactilemedical.com.

For those unable to participate, a replay of the call will be available for two weeks at 877-660-6853 (201-612-7415 for international callers); access code 13754589. The webcast will be archived at investors.tactilemedical.com.

About Tactile Systems Technology, Inc. (DBA Tactile Medical)

Tactile Medical is a leader in developing and marketing at-home therapies for people suffering from underserved, chronic conditions including lymphedema, lipedema, chronic venous insufficiency and chronic pulmonary disease by helping them live better and care for themselves at home. Tactile Medical collaborates with clinicians to expand clinical evidence, raise awareness, increase access to care, reduce overall healthcare costs and improve the quality of life for tens of thousands of patients each year.

Investor Inquiries:
Sam Bentzinger
Gilmartin Group
investorrelations@tactilemedical.com

FAQ

When will Tactile Medical (TCMD) report Q2 2025 earnings?

Tactile Medical will release Q2 2025 earnings on Monday, August 4, 2025 after market close, followed by a conference call at 5:00 p.m. Eastern Time.

How can investors access Tactile Medical's Q2 2025 earnings call?

Investors can access the call by dialing 877-407-3088 (201-389-0927 for international) with access code 13754589, or via webcast on investors.tactilemedical.com.

What medical conditions does Tactile Medical (TCMD) treat?

Tactile Medical provides at-home therapies for chronic conditions including lymphedema, lipedema, chronic venous insufficiency, and chronic pulmonary disease.

Will there be a replay available for Tactile Medical's Q2 2025 earnings call?

Yes, a replay will be available for two weeks by calling 877-660-6853 (201-612-7415 for international) with access code 13754589. The webcast will be archived on the company's investor website.